Patent · US Active

2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors

US8188288B2 · kind B2 · utility

1Cited by

3References

21Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Denis Carniato · Marcoussis, FR
Christine Charon · Gometz-le-Châtel, FR
Johannes Gleitz · Darmstadt, DE
Didier Roche · Écully, FR
Bjoern Hock · Maintal, DE

Key dates

Filing date	Nov 22, 2006
Grant date	May 29, 2012
Priority date	—
Expiry date	Nov 14, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2603/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.